235 related articles for article (PubMed ID: 22161689)
1. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
2. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
3. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
4. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793
[TBL] [Abstract][Full Text] [Related]
5. Ligand-dependent EphB4 activation serves as an anchoring signal in glioma cells.
Kawahara Y; Furuta T; Sabit H; Tamai S; Dong Y; Jiapaer S; Zhang J; Zhang G; Oishi M; Miyashita K; Hayashi Y; Nakada M
Cancer Lett; 2019 May; 449():56-65. PubMed ID: 30776480
[TBL] [Abstract][Full Text] [Related]
6. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Noren NK; Foos G; Hauser CA; Pasquale EB
Nat Cell Biol; 2006 Aug; 8(8):815-25. PubMed ID: 16862147
[TBL] [Abstract][Full Text] [Related]
7. Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: implications for xenograft models of human prostate cancer.
Lisle JE; Mertens-Walker I; Stephens CR; Stansfield SH; Clements JA; Herington AC; Stephenson SA
Exp Cell Res; 2015 Apr; 333(1):136-46. PubMed ID: 25724897
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.
Bhatia S; Oweida A; Lennon S; Darragh LB; Milner D; Phan AV; Mueller AC; Van Court B; Raben D; Serkova NJ; Wang XJ; Jimeno A; Clambey ET; Pasquale EB; Karam SD
Cancer Res; 2019 May; 79(10):2722-2735. PubMed ID: 30894369
[TBL] [Abstract][Full Text] [Related]
9. Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue.
Ozgür E; Heidenreich A; Dagtekin O; Engelmann U; Bloch W
Urol Oncol; 2011; 29(1):78-84. PubMed ID: 19272799
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
11. EphB and Ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells.
Nguyen TM; Arthur A; Hayball JD; Gronthos S
Stem Cells Dev; 2013 Oct; 22(20):2751-64. PubMed ID: 23711177
[TBL] [Abstract][Full Text] [Related]
12. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Masood R; Kumar SR; Sinha UK; Crowe DL; Krasnoperov V; Reddy RK; Zozulya S; Singh J; Xia G; Broek D; Schönthal AH; Gill PS
Int J Cancer; 2006 Sep; 119(6):1236-48. PubMed ID: 16615113
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells.
Hamada K; Oike Y; Ito Y; Maekawa H; Miyata K; Shimomura T; Suda T
Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):190-7. PubMed ID: 12588758
[TBL] [Abstract][Full Text] [Related]
14. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts.
Kwan Tat S; Pelletier JP; Amiable N; Boileau C; Lajeunesse D; Duval N; Martel-Pelletier J
Arthritis Rheum; 2008 Dec; 58(12):3820-30. PubMed ID: 19035475
[TBL] [Abstract][Full Text] [Related]
15. Involvement of endothelial ephrin-B2 in adhesion and transmigration of EphB-receptor-expressing monocytes.
Pfaff D; Héroult M; Riedel M; Reiss Y; Kirmse R; Ludwig T; Korff T; Hecker M; Augustin HG
J Cell Sci; 2008 Nov; 121(Pt 22):3842-50. PubMed ID: 18957513
[TBL] [Abstract][Full Text] [Related]
16. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
Xiong C; Wen Y; Zhao J; Yin D; Xu L; Chelariu-Raicu A; Yao C; Leng X; Liu J; Chaudhari RR; Zhang S; Sood AK; Li C
Sci Rep; 2020 Jan; 10(1):520. PubMed ID: 31949258
[TBL] [Abstract][Full Text] [Related]
17. Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.
Bai J; Wang YJ; Liu L; Zhao YL
J Int Med Res; 2014 Apr; 42(2):405-15. PubMed ID: 24517927
[TBL] [Abstract][Full Text] [Related]
18. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development.
Cowan CA; Yokoyama N; Saxena A; Chumley MJ; Silvany RE; Baker LA; Srivastava D; Henkemeyer M
Dev Biol; 2004 Jul; 271(2):263-71. PubMed ID: 15223333
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of the receptor tyrosine kinase EphB4 and its ligand Ephrin-B2 during human placental development.
Chennakesava CS; Di Santo S; Ziemiecki A; Schneider H; Andres AC
Placenta; 2006; 27(9-10):959-67. PubMed ID: 16343615
[TBL] [Abstract][Full Text] [Related]
20. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
